Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 464582

Aripiprazole: An overview of a novel antipsychotic


Uzun, Suzana; Kozumplik, Oliver; Mimica, Ninoslav; Folnegović-Šmalc, Vera
Aripiprazole: An overview of a novel antipsychotic // Psychiatria Danubina, 17 (2005), 1-2; 67-75 (podatak o recenziji nije dostupan, pregledni rad, stručni)


CROSBI ID: 464582 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Aripiprazole: An overview of a novel antipsychotic

Autori
Uzun, Suzana ; Kozumplik, Oliver ; Mimica, Ninoslav ; Folnegović-Šmalc, Vera

Izvornik
Psychiatria Danubina (0353-5053) 17 (2005), 1-2; 67-75

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, stručni

Ključne riječi
aripiprazole; pharmacotherapy; efficasy; pharmacokinetics; pharmacodynamics; adverse events; clinical trials; drug interactions; dosage; therapy

Sažetak
Aripiprazole exhibits high affinity for dopamine D2 and D3, serotonin 5-HT1A and 5-HT2A receptors, moderate affinity for dopamine D4, serotonin 5-HT2C and 5-HT7, alpha1-adrenergic and histamine Hl receptors. The mean elimination half-lives are about 75 hours and 94 hours for aripiprazole and dehydroaripiprazole, respectively. Steady-state concentrations are attained within 14 days of dosing for both active moieties. At least 1 to 2 weeks, and sometimes up to 4 weeks, may pass before aripiprazole reaches its full effect. The efficacy of aripiprazole was investigated in the treatment of schizophrenia, in the treatment of acute manic episode associated with Bipolar 1 Disorder, and in the treatment of psychosis associated with Alzheimer's dementia. Aripiprazole has demonstrated superiority to placebo in clinical studies of the treatment of both schizophrenia and acute bipolar mania. Aripiprazole has been evaluated for safety in 5592 patients who participated in multiple dose, premarketing trials in schizophrenia, bipolar mania, and dementia of the Alzheimer's type. The recommended starting and target dose for aripiprazole is 10 or 15 mg/day administered on a once-a-day schedule without regard to meals. Aripiprazole has been systematically evaluated and shown to be effective in a dose range of 10 to 30 mg/day. Dosage increases should not be made before 2 weeks of continuous therapy, the time needed to achieve steady state. At least 1 to 2 weeks, and sometimes up to 4 weeks, may pass before aripiprazole reaches its full effect. In this presentation was given an overview of novel antipsychotic aripiprazole.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Projekti:
108-1083509-3511 - Nuspojave psihofarmaka u bolesnika s psihotičnim i afektivnim poremećajima (Uzun, Suzana, MZOS ) ( POIROT)

Ustanove:
Medicinski fakultet, Zagreb,
Klinika za psihijatriju Vrapče


Citiraj ovu publikaciju

Uzun, Suzana; Kozumplik, Oliver; Mimica, Ninoslav; Folnegović-Šmalc, Vera
Aripiprazole: An overview of a novel antipsychotic // Psychiatria Danubina, 17 (2005), 1-2; 67-75 (podatak o recenziji nije dostupan, pregledni rad, stručni)
Uzun, S., Kozumplik, O., Mimica, N. & Folnegović-Šmalc, V. (2005) Aripiprazole: An overview of a novel antipsychotic. Psychiatria Danubina, 17 (1-2), 67-75.
@article{article, year = {2005}, pages = {67-75}, keywords = {aripiprazole, pharmacotherapy, efficasy, pharmacokinetics, pharmacodynamics, adverse events, clinical trials, drug interactions, dosage, therapy}, journal = {Psychiatria Danubina}, volume = {17}, number = {1-2}, issn = {0353-5053}, title = {Aripiprazole: An overview of a novel antipsychotic}, keyword = {aripiprazole, pharmacotherapy, efficasy, pharmacokinetics, pharmacodynamics, adverse events, clinical trials, drug interactions, dosage, therapy} }
@article{article, year = {2005}, pages = {67-75}, keywords = {aripiprazole, pharmacotherapy, efficasy, pharmacokinetics, pharmacodynamics, adverse events, clinical trials, drug interactions, dosage, therapy}, journal = {Psychiatria Danubina}, volume = {17}, number = {1-2}, issn = {0353-5053}, title = {Aripiprazole: An overview of a novel antipsychotic}, keyword = {aripiprazole, pharmacotherapy, efficasy, pharmacokinetics, pharmacodynamics, adverse events, clinical trials, drug interactions, dosage, therapy} }

Časopis indeksira:


  • Scopus
  • MEDLINE


Uključenost u ostale bibliografske baze podataka:


  • MEDLINE





Contrast
Increase Font
Decrease Font
Dyslexic Font